IRVINE, Calif.--(BUSINESS WIRE)--Spectrum Pharmaceuticals, Inc. (NasdaqGM: SPPI) today announced that extended follow-up data for the ZEVALIN® ([90Y]-ibritumomab tiuxetan) First-line Indolent (FIT) study presented at the American Society of Hematology (ASH) Annual Meeting by Morschhauser, et al demonstrated the continued improvement in progression-free survival (PFS) following ZEVALIN consolidation therapy for patients with follicular B-cell non-Hodgkin’s lymphoma who achieved a response to first-line therapy over chemotherapy alone. Additionally, ZEVALIN consolidation did not adversely affect the use of various effective second-line treatments including stem cell transplants in patients who relapsed.
